Solid Biosciences files prospectus for up to $200 million at-the-market stock offering
SLDB•Prior sales under the same agreement
About $85 million of common stock has already been sold under the prior prospectus supplement tied to the same sales agreement.
The new prospectus supplement replaces the prior $85 million program for any future sales under the agreement.
Prospectus supplement filed for at-the-market offering
Solid Biosciences filed a prospectus supplement for an at-the-market offering of up to $200 million of common stock via Jefferies.
The sales program runs under a Form S-3 shelf registration statement that became effective May 27, 2025.
